Prognostische Faktoren und Evaluationskriterien

  • J.A. Burgers


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6(3):527–535PubMedGoogle Scholar
  2. Ando M, Ando Y, Hasegawa Y et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001; 85(11): 1634–1639CrossRefPubMedGoogle Scholar
  3. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6(1): 147–153PubMedGoogle Scholar
  4. Bard M, Ruffie P. Malignant pleural mesothelioma. From diagnosis to prognosis. Presse Med 2002; 31(9): 406–411PubMedGoogle Scholar
  5. Beer TW, Buchanan R, Matthews AW, Stradling R, Pullinger N, Pethybridge RJ. Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 1998; 29(3): 246–251CrossRefPubMedGoogle Scholar
  6. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001; 38(6): 535–541CrossRefPubMedGoogle Scholar
  7. Beer TW. Immunohistochemical MIB-1 and p27 as prognostic factors in pleural mesothelioma. Pathol Res Pract 2001;197(12): 859PubMedGoogle Scholar
  8. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Jama 1996; 276(8): 637–639CrossRefPubMedGoogle Scholar
  9. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999; 40(8): 1241–1245PubMedGoogle Scholar
  10. Bongiovanni M, Cassoni P, De Giuli P et al. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001; 92(5): 1245–1250CrossRefPubMedGoogle Scholar
  11. Boutin C, Rey F, Gouvernet J. Le mésothéliome malin: facteurs pronostiques dans une série de125 patients étudiés de 1973 à 1987. Bull Acad Natl Med 1992; 176(1): 105–114; discussion 115–117PubMedGoogle Scholar
  12. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976; 31(1): 15–24Google Scholar
  13. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34(2): 279–287CrossRefPubMedGoogle Scholar
  14. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746–755PubMedGoogle Scholar
  15. Chailleux E, Dabouis G, Pioche D et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988; 93(1): 159–162Google Scholar
  16. Comin CE, Anichini C, Boddi V, Novelli L, Dini S. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000; 36(1): 26–31CrossRefPubMedGoogle Scholar
  17. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16(1): 145–152PubMedGoogle Scholar
  18. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61(6): 924–926PubMedGoogle Scholar
  19. De Pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993; 72(2): 410–417PubMedGoogle Scholar
  20. Drew PJ, Ilstrup DM, Kerin MJ, Monson JR. Prognostic factors: guidelines for investigation design and state of the art analytical methods. Surg Oncol 1998; 7(1–2): 71–76PubMedGoogle Scholar
  21. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55(9): 731–735CrossRefPubMedGoogle Scholar
  22. Edwards JG, Cox G, Andi A et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001; 85(6): 863–868CrossRefPubMedGoogle Scholar
  23. Emri S, Akbulut H, Zorlu F et al. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer 2001; 33(2–3): 109–114PubMedGoogle Scholar
  24. Esposito V, Baldi A, De Luca A et al. Role of PCNA in differentiating between malignant mesothelioma and mesothelial hyperplasia: prognostic considerations. Anticancer Res 1997; 17(1B): 601–604PubMedGoogle Scholar
  25. Fusco V, Ardizzoni A, Merlo F et al. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Res 1993; 13(3): 683–689PubMedGoogle Scholar
  26. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000; 92(3): 179–181CrossRefPubMedGoogle Scholar
  27. Gospodarowcz M, O’sullivan B. Prognostic factors: principles and application. In: Gospodarowicz M, Henson D, O’sulli-van B, Sobin L, Wittekind C (eds) Prognostic factors in cancer. 2nd edn. Wiley-Liss, New York 2001, pp 17–35Google Scholar
  28. Hegmans JP, Radosevic K, Voerman JS, Burgers JA, Hoogsteden HC, Prins JB. A model system for optimising the selection of membrane antigen-specific human antibodies on intact cells using phage antibody display technology. J Immunol Methods 2002; 262(1–2): 191–204PubMedGoogle Scholar
  29. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113(3): 723–731PubMedGoogle Scholar
  30. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. Jama 2002; 287(21): 2801–2804CrossRefPubMedGoogle Scholar
  31. Isobe H, Sridhar KS, Doria R et al. Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma. Cyto-metry 1995; 19(1): 86–91Google Scholar
  32. Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 1996; 109(1): 109–114PubMedGoogle Scholar
  33. Karnofsky D, Adelmann W, Craver L. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634–656Google Scholar
  34. Klaveren RJ van, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for the response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004; 43: 63–69PubMedGoogle Scholar
  35. Kumar-Singh S, Vermeulen PB, Weyler J et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997; 182(2): 211–216CrossRefPubMedGoogle Scholar
  36. Kumar-Singh S, Jacobs W, Dhaene K et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998; 186(3): 300–305CrossRefPubMedGoogle Scholar
  37. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol 1999; 189(1): 72–78CrossRefPubMedGoogle Scholar
  38. Levene AP, Morgan GJ, Davies FE. The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies. Clin Lab Haematol 2003; 25(4): 209–220CrossRefPubMedGoogle Scholar
  39. Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000; 60(14): 3696–3700PubMedGoogle Scholar
  40. Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001; 20(6): 1117–1121CrossRefPubMedGoogle Scholar
  41. Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001; 78(3): 171–174CrossRefPubMedGoogle Scholar
  42. Metintas M, Metintas S, Ucgun I et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 2001; 95(10): 829–835PubMedGoogle Scholar
  43. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1): 207–214PubMedGoogle Scholar
  44. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3(7): 425–430CrossRefPubMedGoogle Scholar
  45. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002; 29(1): 82–96CrossRefPubMedGoogle Scholar
  46. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81(1): 54–61CrossRefPubMedGoogle Scholar
  47. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998; 115(2): 310–317; discussion 317–318PubMedGoogle Scholar
  48. Pyrhönen S, Laasonen A, Tammilehto L et al. Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma. Eur J Cancer 1991; 27(2): 197–200PubMedGoogle Scholar
  49. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7(8): 1157–1168PubMedGoogle Scholar
  50. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108(4): 1122–1128PubMedGoogle Scholar
  51. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999; 68(5): 1799–1804CrossRefPubMedGoogle Scholar
  52. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Prognos-tic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999; 25(1): 25–32CrossRefPubMedGoogle Scholar
  53. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epidemiol 2000; 53(10): 973–979CrossRefPubMedGoogle Scholar
  54. Simon R. Evaluating prognostic factor studies. In: Gospodarowicz M, Henson D, O’sullivan B, Sobin L, Wittekind C (eds) Prognostic factors in cancer. 2nd edn. Wiley-Liss, New York 2001, pp 49–56Google Scholar
  55. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988; 41(4): 525–530PubMedGoogle Scholar
  56. Steele JP. Prognostic factors in mesothelioma. Semin Oncol 2002; 29(1): 36–40CrossRefPubMedGoogle Scholar
  57. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117(1): 54–63; discussion 63–65PubMedGoogle Scholar
  58. Sugarbaker DJ, Strauss GM, Lynch TJ et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993; 11(6): 1172–1178PubMedGoogle Scholar
  59. Tammilehto L, Kivisaari L, Salminen US, Maasilta P, Mattson K. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients. Lung Cancer 1995; 12(1–2): 25–34PubMedGoogle Scholar
  60. Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992; 8: 175–184CrossRefGoogle Scholar
  61. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205–216CrossRefPubMedGoogle Scholar
  62. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001; 92(5): 1224–1230PubMedGoogle Scholar
  63. van’ t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871): 530–536Google Scholar
  64. WHO. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland, 1979Google Scholar
  65. Winegarden N. Microarrays in cancer: moving from hype to clinical reality. Lancet 2003; 362(9394): 1428CrossRefPubMedGoogle Scholar
  66. Wong CF, Fung SL, Yew WW, Fu KH. A case of malignant pleural mesothelioma with unexpectedly long survival without active treatment. Respiration 2002; 69(2): 166–168CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2005

Authors and Affiliations

  • J.A. Burgers
    • 1
  1. 1.Department of Respiratory DiseasesUniversity Hospital RotterdamRotterdamThe Netherlands

Personalised recommendations